Navigation Links
EntreMed Reports Third Quarter 2008 Financial Results
Date:11/6/2008

tiated in 2006 and 2007. We expect research and development expenses to trend down in the fourth quarter and into 2009 as we collect clinical data and evaluate each program to determine future clinical direction. At the end of the quarter we reported $27.9 million in cash and short-term investments, which together with anticipated royalty inflows, we believe will fund planned operations for at least the next 12 months."

James S. Burns, EntreMed President and Chief Executive Officer, commented, "We are actively pursuing partners for ENMD-2076 and Panzem(R) RA while continuing our clinical oncology programs, including the Phase 1b dose-escalation study in solid tumors for ENMD-2076. The outcome of our partnering initiatives and anticipated clinical progress will guide our priorities through year-end and into 2009. While we are reducing overall expenses, our clinical trials remain on schedule. We anticipate the presentation of clinical and preclinical data for MKC-1, ENMD-2076 and ENMD-1198 over the next several quarters."

Mr. Burns will present a Company overview at the Rodman & Renshaw 10th Annual Healthcare Conference, which will serve as the Company's third quarter 2008 update. Mr. Burns' presentation is scheduled for 2:25 p.m. (ET) on Tuesday, November 11, 2008 and will be web cast. To access the live presentation, visit the Company's web site at http://www.entremed.com. An archive of the presentation will be available on the web site for approximately 90 days.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway, is currently in multiple Phase 2 clinical trials for cancer. ENMD-2076, a selective angiogenic kinase inhibitor, and ENMD-1198, a novel antimitotic agent are in Phase 1 studies in advanced canc
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
2. EntreMed to Present at BioPartnering Europe Conference
3. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
4. EntreMed Reports Second Quarter 2008 Financial Results
5. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
6. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
7. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
8. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
9. EntreMed Receives Nasdaq Deficiency Notice
10. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
11. EntreMed Announces 2008 Corporate and Clinical Program Priorities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... VA (PRWEB) January 15, 2014 Two ... have continued their sponsorship of an annual competition for ... in, and access to, innovative STEM study. The competition ... TEAMS: Tests of Engineering Aptitude, Mathematics, and Sciences ...
(Date:1/15/2014)... CA (PRWEB) January 15, 2014 ... research solutions, today announced that Lupin Limited, one of ... Freeslate’s CM Protégé PharmD System for high ... Mumbai, India, is focused on a wide range of ...
(Date:1/14/2014)... 2014 Carahsoft and CDS Federal Services ... 2014 at 2pm EST (11am PST), “Natural Language Processing: ... on how technology can turn raw, heterogeneous data into ... agencies. The online webinar will last approximately one hour. ...
(Date:1/14/2014)... New York, NY (PRWEB) January 14, 2014 ... coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an ... products to serve the wound care market. , Free ... Alliqua was restructured with a seasoned management team and ...
Breaking Biology Technology:Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... If you're on the Midwest technology job market today, ... You've also learned something about interviewing, thank-you letters and ... ,If youre an older job seeker, though, you may ... to surmount your search: your age. Wait. Isn't age ...
... the weeks since, I've been asked many times why the ... of course, one very practical reason: No compelling new services ... that's the easy out. , ,As I've written before, social ... a clear avenue to revenue that returns value to customers ...
... Wisconsin-based businesses and organizations have formed a unique ... efforts of the Medical College of Wisconsin Research ... commercialization activities. The foundation announced the funding along ... Marketing and Licensing, whose primary purpose will be ...
Cached Biology Technology:How 40-plus tech job seekers can prevent age discrimination 2How 40-plus tech job seekers can prevent age discrimination 3How 40-plus tech job seekers can prevent age discrimination 4Social Networks Revisited 2Social Networks Revisited 3Medical College gets support to expand technology commercialization 2Medical College gets support to expand technology commercialization 3Medical College gets support to expand technology commercialization 4
(Date:4/18/2014)... researchers led by a University of California, Riverside professor ... million Department of Defense grant to uncover fundamental design ... the predictable design of light-weight, tough and strong advanced ... plants and animals, including the mantis shrimp, toucan and ... constructed over millions of years and coming up with ...
(Date:4/17/2014)... of stem cell therapies to cure a variety of ... populations based on cell surface markers. Researchers from the ... is highly expressed in a type of stem cells ... in an article in BioResearch Open Access , ... The article is available free on the ...
(Date:4/17/2014)... births, Down syndrome - or trisomy 21 - is ... results from a chromosomal abnormality where cells of affected ... of the human genome). A study conducted by Stylianos ... Medicine and Development at the University of Geneva (UNIGE) ... light on how the extra chromosome 21 upsets the ...
Breaking Biology News(10 mins):Mantis shrimp, toucan and trilobite, oh my 2Mantis shrimp, toucan and trilobite, oh my 3Trisomy 21: How an extra little chromosome throws the entire genome off balance 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 3
... soldier is wounded during combat, surgeons must focus on ... that could improve the repair and regeneration processes are ... they are not being moved quickly enough into military ... Tech Center for Advanced Bioengineering for Soldier Survivability want ...
... person who dies suddenly should always be referred for ... they too are at risk of sudden death, a ... of Human Genetics today (Tuesday 26 May). ... the Department of Cardiogenetics, Academic Medical Centre, Amsterdam, The ...
... IMMEDIATE RELEASE An advance in solving the mysterious ... Scientists in Ohio are reporting a ... than one million machinists in the United States who ... fluids. Those fluids become airborne during machining of metal ...
Cached Biology News:New center at Georgia Tech aims to improve recovery of soldiers with severe injuries 2New center at Georgia Tech aims to improve recovery of soldiers with severe injuries 3Comprehensive cardiogenetic testing for families of sudden unexplained death victims can save lives 2American Chemical Society's Weekly PressPac -- May 20, 2009 2American Chemical Society's Weekly PressPac -- May 20, 2009 3American Chemical Society's Weekly PressPac -- May 20, 2009 4American Chemical Society's Weekly PressPac -- May 20, 2009 5American Chemical Society's Weekly PressPac -- May 20, 2009 6American Chemical Society's Weekly PressPac -- May 20, 2009 7American Chemical Society's Weekly PressPac -- May 20, 2009 8American Chemical Society's Weekly PressPac -- May 20, 2009 9American Chemical Society's Weekly PressPac -- May 20, 2009 10
Request Info...
...
... Radiochemical Purity is >95%\nNEN Radiolabeled Ligands\n\nReceptor-related research ... availability of new radiolabeled ligands selected to ... a wide range of products and services ... over 400 state-of-the-art radioligands. If you do ...
Request Info...
Biology Products: